CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.75
0.01 (0.83%)
â˛
5d:
+1.35%
30d:
+33.4%
90d:
-10.7%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CTOR is fairly priced but lacks strong directional signals. At 22.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CTOR is fairly priced but lacks strong directional signals. At 22.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.75, which is considered slightly high relative to its 30-day fair value range of $0.58 to $0.78. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.5) compared to its historical average (4.1). At these levels, the market is pricing in 22.7% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.94.
Market Sentiment: CTOR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+433.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.94.
Market Sentiment: CTOR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+433.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.58 -
$0.78
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
38.1%
All Signals
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 433.3% below Wall St target ($4.00)
- BEARISH: Market expects 22.7% growth - appears too optimistic based on history
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.58 -
$0.78
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.94
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.50
Wall Street Target
$4.00
(+433.3%)
Valuation Premium vs History
+22.7% premium
PE vs Historical
7.5 vs 4.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+22.7%
(market-implied from PE analysis)
1-Year Target
$0.92
(+23%)
2-Year Target
$1.13
(+51%)
3-Year Target
$1.39
(+85%)
3-Yr Target (if PE normalizes)
(PE: 8â4)
PE COMPRESSION
$0.76
(+1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 24, 2026 6:36 PM ET
Data refreshes hourly during market hours. Next update: 7:36 PM
Data refreshes hourly during market hours. Next update: 7:36 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |